BAM
ATYR

Belpointe Asset Management’s aTyr Pharma ATYR Stock Holding History

Belpointe Asset Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-45,738
Closed -$35.7K – 1243
2026
Q1 		$35.7K Buy
45,738
+35,300
+338% +$29.8K ﹤0.01% 1057
2025
Q4 		$8.17K Hold
10,438
– – ﹤0.01% 1019
2025
Q3 		$7.53K Buy
+10,438
New +$47.3K ﹤0.01% 980

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Belpointe Asset Management's ATYR Position: Q2 2026 in Review

Belpointe Asset Management sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 45,738 shares — an estimated $35.7K sold.

Belpointe Asset Management first reported a position in ATYR in Q3 2025 and held it in 3 quarters. The position peaked at $35.7K in Q1 2026. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Belpointe Asset Management reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
  • Belpointe Asset Management sold 45,738 aTyr Pharma shares in Q2 2026, an estimated $35.7K.
  • Belpointe Asset Management first reported a position in aTyr Pharma in Q3 2025 and held it in 3 quarters.
  • Belpointe Asset Management's aTyr Pharma position peaked at $35.7K in Q1 2026.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.